Renalytix plc
("Renalytix" or the "Company")
Directorate change
LONDON and SALT LAKE CITY - October 24, 2023 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), the first company to commercialize an FDA authorized artificial intelligence (AI) enabled blood test to assess risk of progressive kidney function decline for individuals with type 2 diabetes and early-stage chronic kidney disease, announces that Timothy Scannell has stepped down from his role as independent Non-Executive Director of Renalytix effective as of October 18, 2023, to pursue other opportunities.
James McCullough, CEO of Renalytix plc, commented: "It has been a wonderful learning experience to work alongside Tim for the past 18 months. He has been a significant contributor to Renalytix, and I would like to thank him for all his efforts on the Board."
For further information, please contact:
|
Renalytix plc |
|
|
James McCullough, CEO |
Via Walbrook PR |
|
Stifel (Nominated Adviser, Joint Broker) |
Tel: 020 7710 7600 |
|
Alex Price / Nicholas Moore / Nick Harland / Samira Essebiyea |
|
|
Investec Bank plc (Joint Broker) |
Tel: 020 7597 4000 |
|
Gary Clarence / Shalin Bhamra |
|
|
Walbrook PR Limited |
Tel: 020 7933 8780 or renalytix@walbrookpr.com |
|
Paul McManus / Alice Woodings |
Mob: 07980 541 893 / 07407 804 654 |
|
CapComm Partners |
|
|
Peter DeNardo |
Tel: 415-389-6400 or investors@renalytix.com |
About Renalytix
Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.